– 26 scientific abstracts, including two oral presentations, demonstrate UCB s ongoing commitment to advancing research for people living with epilepsies
– Data include an open-label extension study describing the long-term safety of FINTEPLA®? (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2]
– Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic cha
Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines.
Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company s newly established Cambridge location, where he will establish a group of world-class biomedical talent as the company advances its work translating AI-driven drug discovery
MedHub-AI (http://www.medhub-ai.com/), pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical accuracy compared to conventional 3D FFR methodologies.
ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.
This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.
A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant under the EIC Transition Programme of Horizon Europe.
The funding will drive the consortium s collaborative efforts to develop NeutroFlow—a novel, point-of-care diagnostic test designed to predict patient response to immune checkpoint inhibitors (ICIs) acros
The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform.
m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, research centers, and companies to develop scalable, personalized grafts for tissue repair.
– Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine
– Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields
The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research.
– Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases.
– The EC approval follows a positive opinion issued on 19 October 2024 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenst
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO").
Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with an undisputed track record of serving a loyal and broad global customer base. With the acquisition of Gentronix, Scantox s service platform expands sign
